After a grueling 15-year long battle, the Texas Medical Board has officially ended its crusade to revoke Dr. Stanislaw Burzynski's medical license in an effort to end his use of Antineoplastons, as well as his combination gene-targeted therapy for cancer.
The Texas Medical Board’s case against him was dismissed1 on November 19, 2012, just in time for Thanksgiving. According to Dr. Burzynski’s attorney, Richard A. Jaffe, Esq:2
“Early on, two medical board informal settlement panels found that the use of these combination drugs on the advanced cancer patients involved was within the standard of care.
However, the Texas Medical Board refused to drop the case and instead filed a formal complaint3 against Dr. Burzynski alleging the same standard of care violations previously rejected by the board settlement panels.
After two years of intense litigation, the case was set for trial in April 2012. However, a week before trial, the administrative law judges dismissed most of the charges against Dr. Burzynski which forced the Board to seek to adjourn the case to do some reevaluation.
After the judges denied the Board’s attempt to reverse the previous partial dismissal of the case, the Board did more reevaluation and moved to dismiss the entire case.”